{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/TCRT/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T19:08:39.387Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":12401,"canonical_name":"Alaunos Therapeutics, Inc.","cik":"0001107421","uei":null,"lei":null,"duns":null,"ticker":"TCRT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":31},"count":31,"timeline":[{"ts":"2026-10-15","kind":"sec.filing","form_type":"SCHEDULE 13D","title":"SCHEDULE 13D — Alaunos Therapeutics, Inc. — 2026-10-15","url_slug":"/sec/cik-0001107421/schedule-13d/0001683168-26-007898","accession_number":"0001683168-26-007898","importance":75},{"ts":"2026-10-15","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Alaunos Therapeutics, Inc. — 2026-10-15","url_slug":"/sec/cik-0001107421/schedule-13d-a/0001193805-26-001370","accession_number":"0001193805-26-001370","importance":70},{"ts":"2026-10-15","kind":"sec.filing","form_type":"3","title":"3 — Alaunos Therapeutics, Inc. — 2026-10-15","url_slug":"/sec/cik-0001107421/3/0001683168-26-007900","accession_number":"0001683168-26-007900","importance":30},{"ts":"2026-10-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Alaunos Therapeutics, Inc. — 2026-10-13","url_slug":"/sec/cik-0001107421/8-k/0001193125-26-419829","accession_number":"0001193125-26-419829","importance":35},{"ts":"2026-10-09","kind":"sec.filing","form_type":"8-K","title":"8-K — Alaunos Therapeutics, Inc. — 2026-10-09","url_slug":"/sec/cik-0001107421/8-k/0001193125-26-419154","accession_number":"0001193125-26-419154","importance":35},{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-10-08","url_slug":"/sec/cik-0001107421/4/0001193125-26-417969","accession_number":"0001193125-26-417969","importance":30},{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-10-08","url_slug":"/sec/cik-0001107421/4/0001193125-26-417970","accession_number":"0001193125-26-417970","importance":30},{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-10-08","url_slug":"/sec/cik-0001107421/4/0001193125-26-417971","accession_number":"0001193125-26-417971","importance":30},{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-10-08","url_slug":"/sec/cik-0001107421/4/0001193125-26-417974","accession_number":"0001193125-26-417974","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Alaunos Therapeutics, Inc. — 2026-09-22","url_slug":"/sec/cik-0001107421/8-k/0001193125-26-397996","accession_number":"0001193125-26-397996","importance":35},{"ts":"2026-09-21","kind":"sec.filing","form_type":"424B3","title":"424B3 — Alaunos Therapeutics, Inc. — 2026-09-21","url_slug":"/sec/cik-0001107421/424b3/0001193125-26-396777","accession_number":"0001193125-26-396777","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Alaunos Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001107421/8-k/0001193125-26-393462","accession_number":"0001193125-26-393462","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Alaunos Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001107421/10-q/0001193125-26-352421","accession_number":"0001193125-26-352421","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001107421/4/0001193125-26-344682","accession_number":"0001193125-26-344682","importance":30},{"ts":"2026-08-06","kind":"sec.insider.a","reporter":"Weis Holger","title":"CEO","shares":4363,"price_per_share":2.01,"usd_value":8770,"security_title":"Common Stock","importance":15.00876963},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001107421/4/0001193125-26-318100","accession_number":"0001193125-26-318100","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001107421/4/0001193125-26-318103","accession_number":"0001193125-26-318103","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001107421/4/0001193125-26-318105","accession_number":"0001193125-26-318105","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001107421/4/0001193125-26-318114","accession_number":"0001193125-26-318114","importance":30},{"ts":"2026-07-23","kind":"sec.insider.a","reporter":"Vieser Jaime","title":null,"shares":8789,"price_per_share":1.92,"usd_value":16875,"security_title":"Common Stock","importance":15.01687488},{"ts":"2026-07-23","kind":"sec.insider.a","reporter":"Postma Robert W","title":null,"shares":8463,"price_per_share":1.92,"usd_value":16249,"security_title":"Common Stock","importance":15.01624896},{"ts":"2026-07-23","kind":"sec.insider.a","reporter":"Jerman Michael Allen","title":null,"shares":8138,"price_per_share":1.92,"usd_value":15625,"security_title":"Common Stock","importance":15.01562496},{"ts":"2026-07-23","kind":"sec.insider.a","reporter":"Weis Holger","title":"CEO","shares":4568,"price_per_share":1.92,"usd_value":8771,"security_title":"Common Stock","importance":15.00877056},{"ts":"2026-07-06","kind":"sec.filing","form_type":"S-8","title":"S-8 — Alaunos Therapeutics, Inc. — 2026-07-06","url_slug":"/sec/cik-0001107421/s-8/0001193125-26-295169","accession_number":"0001193125-26-295169","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001107421/4/0001193125-26-295004","accession_number":"0001193125-26-295004","importance":30},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Weis Holger","title":"Chief Executive Officer","shares":3880,"price_per_share":2.26,"usd_value":8769,"security_title":"Common Stock","importance":15.0087688},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Alaunos Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001107421/8-k/0001193125-26-286914","accession_number":"0001193125-26-286914","importance":35},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Alaunos Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001107421/4/0001193125-26-274305","accession_number":"0001193125-26-274305","importance":30},{"ts":"2026-06-12","kind":"sec.insider.a","reporter":"Weis Holger","title":"Chief Executive Officer","shares":7761,"price_per_share":2.26,"usd_value":17540,"security_title":"Common Stock","importance":15.01753986},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Alaunos Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001107421/8-k/0001193125-26-227921","accession_number":"0001193125-26-227921","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Alaunos Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001107421/10-q/0001193125-26-227272","accession_number":"0001193125-26-227272","importance":45}]}